Virtual CME Program

From Guidelines to Practice: Updates in the Management of T2DM and Obesity

Get up to speed on evolving strategies in diabetes care and cardiometabolic health. Explore guideline changes around pharmacologic sequencing, weight management, and comorbidity prevention—all designed to help you personalize therapy and improve outcomes across your panel.

CME/CE Information

0 Credits - Not for CME/CE Credit

Release Date: 4/1/2026

Expiration Date: 5/1/2026

Topics

Faculty

Martin J. Abrahamson, MD, FACP

Learning Objectives

Summarize recent updates in diabetes prevention, screening, diagnosis, and treatment, including evolving criteria for at-risk populations
Apply current recommendations for pharmacologic sequencing, weight management, and cardiometabolic risk reduction
Integrate emerging therapies and guideline changes into individualized, evidence-based care plans across the continuum of diabetes management

Faculty

Martin J. Abrahamson, MD, FACP

Associate Professor of Medicine, Harvard Medical School, Boston, MA

Director, Division of CME, Beth Israel Medical Center, Beth Israel Deaconess Medical Center, Boston, MA

Learn More

Disclosures

All individuals in control of content for this activity (including faculty, moderator, editors, reviewers) have disclosed no relevant financial relationships.

Fine Print

Computer System Requirements

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

Disclaimer

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Statement of Independence

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Disclosure Policies and Contacting Pri-Med Institute

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.